Search the Studies

389 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number Title Protocol Status Min-Max Age Institute Keywords
000491-CTissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)Participants currently recruited/enrolled18-125 YearsNCI Appendix Carcinoid Tumor
000237-CPhase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis from Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary CancerParticipants currently recruited/enrolled18-125 YearsNCI Appendix Tumor
19-C-0138Phase I/II Study of Lu-177-DOTATATE (Lutathera) in Combination with Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)Participants currently recruited/enrolled18-125 YearsNCI Carcinoid Tumor
19-C-0016Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid TumorsParticipants currently recruited/enrolled0-125 YearsNCI Carcinoid Tumor
15-C-0099A Phase 1, Open-Label, Dose-Escalation Study of SNX-5422 and Everolimus in Subjects with Neuroendocrine TumorsCompleted Study; data analyses ongoing18-100 YearsNCI Carcinoid Tumor
08-DK-0098Natural History of Familial Carcinoid TumorParticipants currently recruited/enrolled18-125 YearsNIDDKCarcinoid Tumor
002090-CComboMATCH Treatment Trial N5: Randomized Trial of Neratinib, a Pan-ErbB Inhibitor alone or in combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and other Solid TumorsParticipants currently recruited/enrolled18-120 YearsNCI Tumor
002056-CPhase 1/1B Study of DS-8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial)Recruitment has not started18-120 YearsNCI Tumor
002041-CPhase 2 Trial of the Combination of the BET inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET)Recruitment has not started18-120 YearsNCI Tumor
001961-CA Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774Participants currently recruited/enrolled18-120 YearsNCI Tumor
001951-CNatural History Study of Kaposi SarcomaParticipants currently recruited/enrolled18-120 YearsNCI Tumor
001924-CA Phase 1, Open-Label, Dose Escalation Study of the Safety and Tolerability of ANK-101 in Advanced Solid TumorsRecruitment has not started18-120 YearsNCI Tumor
001920-CA ComboMATCH Treatment Trial: FOLFOX In Combination With Binimetinib As 2nd Line Therapy For Patients With Advanced Biliary Tract Cancers With MAPK Pathway AlterationsParticipants currently recruited/enrolled18-120 YearsNCI Tumor
001886-CA Phase 1 Study of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial CancersParticipants currently recruited/enrolled18-120 YearsNCI Tumor
001859-CA Phase I Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent GlioblastomaRecruitment has not started18-120 YearsNCI Tumor
001827-CPhase 3, Multicenter, Randomized, Open-Label Study to Assess the Efficacy and Safety Of the Lifileucel (LN-144), Autologous Tumor-Infiltrating Lymphocytes [TIL]) Regimen in Combination with Pembrolizumab Compared with Pembrolizumab Monotherapy in ParticiRecruitment has not started18-70 YearsNCI Tumor
001826-CA Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems using Pupillometry in Participants with Neurofibromatosis Type 1 (NF1)Recruitment has not started1-120 YearsNCI Tumor
001783-CAn Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-Directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants With Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CAR T-celParticipants currently recruited/enrolled18-120 YearsNCI Tumor
001778-CA Randomized, Open Label, Two-Arm, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination with Pembrolizumab Versus Pembrolizumab Monotherapy in Patients with Recurrent or Metastatic Cervical CancerParticipants currently recruited/enrolled18-120 YearsNCI Tumor
001776-CA Phase 1 Dose Escalation and Expansion Study of GIGA-564, a Minimally Blocking Anti-CTLA-4 Monoclonal Antibody, in Participants with Locally Advanced or Metastatic Solid Tumor MalignanciesParticipants currently recruited/enrolled18-120 YearsNCI Tumor
001771-CEAY191-S3, Phase II Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants With AKT-Altered Advanced Non-Breast Solid Tumors (A ComboMATCH Treatment Trial)Participants currently recruited/enrolled18-100 YearsNCI Tumor
001770-CMolecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial CancersParticipants currently recruited/enrolled18-120 YearsNCI Tumor
001756-CA Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients with Metastatic Leiomyosarcoma and Other Soft Tissue SarcomasParticipants currently recruited/enrolled18-120 YearsNCI Tumor
001749-CComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid TumorsParticipants currently recruited/enrolled18-120 YearsNCI Tumor
001733-CA Phase 1 Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal CarcinomaParticipants currently recruited/enrolled18-100 YearsNCI Tumor
001732-CA Phase 1 Study of the Polymerase Theta (POL-Theta) Inhibitor Novobiocin in BRCA-mutant and Other DNA Damage Repair-Deficient Solid TumorsParticipants currently recruited/enrolled18-120 YearsNCI Tumor
001731-C18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer DetectionRecruitment has not started18-120 YearsNCI Tumor
001730-CPhase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination with Immunotherapy Vaccine PRGN-2009 in Subjects with Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) CancerParticipants currently recruited/enrolled18-120 YearsNCI Tumor
001715-CA Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VHL) Disease-AssociParticipants currently recruited/enrolled12-120 YearsNCI Tumor
001711-CPhase I/II Trial of Systemic Targeted Radioligand Therapy (TRT) with Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR Positive (SSTR+) Gastrointestinal (GI) Neuroendocrine Tumors (NET) and Pheochromocytoma/ParagRecruitment has not started18-120 YearsNCI Tumor
001709-CPhase I Trial of [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck CancersRecruitment has not started18-120 YearsNCI Tumor
001704-CRandomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue SarcomaClinical hold/Recruitment or enrollment suspended18-100 YearsNCI Tumor
001696-CSurveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)Recruitment has not started3-120 YearsNCI Tumor
001695-CA Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (anti-VISTA) as Monotherapy and in Combination with Cemiplimab in Patients with Advanced Solid TumorsRecruitment has not started18-120 YearsNCI Tumor
001691-CA Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants with Primary Colorectal or Gastroesophageal CancerRecruitment has not started18-120 YearsNCI Tumor
001665-CMolecular Analysis for Combination Therapy Choice (ComboMATCH)Participants currently recruited/enrolled2-120 YearsNCI Tumor
001662-CA Phase Ib Clinical Trial to Evaluate the Administration of Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction with a Vaccine Directed Against these Antigens in Participants with Metastatic CanceParticipants currently recruited/enrolled18-72 YearsNCI Tumor
001657-CPhase 1 Umbrella Trial of Erlotinib In Combination with Select Tyrosine Kinase Inhibitors In Adult Patients with Advanced Solid TumorsRecruitment has not started18-120 YearsNCI Tumor
001608-NPre-operative vs. Post-operative Stereotactic Radiosurgery for Operative Metastatic Brain TumorsParticipants currently recruited/enrolled18-99 YearsNINDSTumor
001601-CA UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and ToxicityRecruitment has not started18-120 YearsNCI Tumor
001600-CPhase 2 Study Evaluating the Functional Status of the Adrenal Glands with [68Ga]Ga-PentixaFor in Hyperaldosteronism and HypercortisolismParticipants currently recruited/enrolled18-120 YearsNCI Tumor
001599-CPhase I/II Trial of Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)Recruitment has not started18-120 YearsNCI Tumor
001591-CPilot Study of CBX-12 Pharmacodynamics in Patients with Advanced Solid TumorsParticipants currently recruited/enrolled18-100 YearsNCI Tumor
001590-CRapid Analysis and Response Evaluation of Combination Anti-neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 3 Tiragolumab + AtezolizumabParticipants currently recruited/enrolled18-100 YearsNCI Tumor
001578-CA Phase 1/2 Study of Tiragolumab (NSC# 827799, IND# 161266) and Atezolizumab (NSC# 783608, IND# 161266) in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient TumorsParticipants currently recruited/enrolled3-100 YearsNCI Tumor
001572-CA Phase II Study of Bevacizumab in Adults with Recurrent Respiratory Papillomatosis (RRP)Participants currently recruited/enrolled18-120 YearsNCI Tumor
001569-CA Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma PatientsRecruitment has not started18-100 YearsNCI Tumor
001564-CA Phase II Sequential Window of Opportunity Trial of Pembrolizumab + N-803 alone or in Combination with PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell CarcinomaRecruitment has not started18-120 YearsNCI Tumor
001563-CPhase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)Participants currently recruited/enrolled18-120 YearsNCI Tumor
001559-CA Feasibility Multicenter Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingRecruitment has not started18-120 YearsNCI Tumor
001557-CPhase I/II Trial of Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination with HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants with Advanced or Metastatic Endometrial Cancer (EC)Participants currently recruited/enrolled18-120 YearsNCI Tumor
001552-CPhase II Study of Enasidenib in IDH2-mutated Malignant Sinonasal and Skull Base TumorsParticipants currently recruited/enrolled18-120 YearsNCI Tumor
001548-CA Phase I/II Study of CDX-1140, a CD40 Agonist, in Combination with Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects with Biliary Tract Carcinoma (BTC)Participants currently recruited/enrolled0-120 YearsNCI Tumor
001547-CA First-in-Human Phase I Trial with Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and CarcinomasParticipants currently recruited/enrolled18-120 YearsNCI Tumor
001545-CA Phase Ib/II Multicenter Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERASRecruitment has not started18-120 YearsNCI Tumor
001536-CPhase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 with Pembrolizumab before Standard Treatment in Subjects with Newly Diagnosed HPV-Associated Oropharyngeal CancerParticipants currently recruited/enrolled18-120 YearsNCI Tumor
001535-CA Phase II Study of Sacituzumab Govitecan with or without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile CancerRecruitment has not started18-120 YearsNCI Tumor
001534-CPhase I/II Trial of PLX038 in Primary Central Nervous System Tumors containing MYC or MYCN AmplificationsParticipants currently recruited/enrolled18-120 YearsNCI Tumor
001533-CA Phase II Multicenter Study of Enfortumab Vedotin with or without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)Recruitment has not started18-120 YearsNCI Tumor
001524-CA Phase I Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T- Cells for Treating B-cell MalignanciesParticipants currently recruited/enrolled18-75 YearsNCI Tumor
001523-CA Phase II Study of Lurbinectedin with or without Avelumab in Small Cell Carcinoma of the Bladder (LASER)Participants currently recruited/enrolled18-120 YearsNCI Tumor
001516-CPhase I Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-Small Cell Lung CancerParticipants currently recruited/enrolled18-120 YearsNCI Tumor
001099-CA Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-Fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors thatParticipants currently recruited/enrolled18-125 YearsNCI Tumor
001004-CA Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon Oncosignature(R) StatusParticipants currently recruited/enrolled18-120 YearsNCI Tumor
000958-CProspective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor MicroenvironmentEnrolling by Invitation18-125 YearsNCI Tumor
000954-CA Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients with Advanced Mesothelin-Expressing CancerNo longer recruiting/follow-up only18-120 YearsNCI Tumor
000930-CA Phase 1b/2 Study of HCW9218, a Bifunctional TGF-beta Antagonist/IL-15 Protein Complex, for Advanced Pancreatic CancerParticipants currently recruited/enrolled18-125 YearsNCI Tumor
000860-CA Phase I/II Study of Zotiraciclib for Recurrent High-Grade Gliomas with Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) MutationsParticipants currently recruited/enrolled18-125 YearsNCI Tumor
000726-CA Randomized Phase 2 Study of Atezolizumab with or without Selinexor in Alveolar Soft Part Sarcoma (AXIOM)Participants currently recruited/enrolled18-125 YearsNCI Tumor
000696-CA Phase III, Multicenter, International Study with a Parallel, Randomized, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants with NF1 who have Symptomatic, Inoperable Plexiform NeurofibrNo longer recruiting/follow-up only18-120 YearsNCI Tumor
000692-CRapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 2 Talazoparib and TemozolomideParticipants currently recruited/enrolled12-125 YearsNCI Tumor
000678-CRare Tumors and Cancer Predisposition in Individuals and FamiliesParticipants currently recruited/enrolled0-125 YearsNCI Tumor
000666-CA Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)Participants currently recruited/enrolled18-100 YearsNCI Tumor
000647-CAn Open-label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Bintrafusp alfa (M7824) Clinical StudiesRecruitment has not started18-120 YearsNCI Tumor
000611-CA Phase II Trial of Focal Ultrahypofractionated Stereotactic Radiation Therapy for the Treatment of Unifocal Prostate CancerParticipants currently recruited/enrolled18-120 YearsNCI Tumor
000596-CPhase II Study of Olaparib in Subjects with Advanced Pancreatic Acinar Cell CarcinomaParticipants currently recruited/enrolled18-125 YearsNCI Tumor
000520-CPhase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG with or without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung CancerClinical hold/Recruitment or enrollment suspended18-125 YearsNCI Tumor
000516-CPhase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma involving the Central Nervous SystemNo longer recruiting/follow-up only18-125 YearsNCI Tumor
000484-CRandomized Phase II Trial of Durvalumab (D) plus Olaparib (O) and Cediranib (C: DOC) Compared to OC or DC or Chemotherapy in Platinum-Resistant Recurrent Ovarian Cancer with Prior BevacizumabNo longer recruiting/follow-up only18-125 YearsNCI Tumor
000481-CPhase II Trial of 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation TherapyParticipants currently recruited/enrolled18-125 YearsNCI Tumor
000475-CPhase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients with Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-deficient Gastrointestinal Stromal Tumor (GIST)Participants currently recruited/enrolled18-125 YearsNCI Tumor
000462-CPhase 2, Open-label, Single-arm, Window of Opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging in Patients With Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell CarcinomaParticipants currently recruited/enrolled18-125 YearsNCI Tumor
000344-DKNatural History Study of Parathyroid DisordersParticipants currently recruited/enrolled0-100 YearsNIDDKTumor
000326-HA Phase 1, Dose Escalation, Safety and Tolerability Study of NX- 2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell MalignanciesParticipants currently recruited/enrolled18-125 YearsNHLBITumor
000324-CPhase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell MalignanciesParticipants currently recruited/enrolled3-39 YearsNCI Tumor
000317-CA Phase II, Open-Label Trial of PT-112 in Subjects with Thymoma and Thymic CarcinomaParticipants currently recruited/enrolled18-120 YearsNCI Tumor
000307-CPhase II Study Evaluating the Efficacy of M9241 in Combination with Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects with Metastatic Colorectal Cancer or Intrahepatic CholangiocarcinomaParticipants currently recruited/enrolled18-125 YearsNCI Tumor
000305-CExploratory Phase II Study of LAnreotide in Unresectable or Metastatic Pheochromocytoma / PARAgangliomaNo longer recruiting/follow-up only18-125 YearsNCI Tumor
000303-CA Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide Vs. Temozolomide and Olaparib For Advanced Pheochromocytoma And ParagangliomaParticipants currently recruited/enrolled18-125 YearsNCI Tumor
000302-CA Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract MalignanciesParticipants currently recruited/enrolled18-125 YearsNCI Tumor
000293-CManaging Cancer and Living Meaningfully (CALM) Therapy in Individuals Diagnosed with a Primary Central Nervous System TumorCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
000274-CPhase I Trial of Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasClinical hold/Recruitment or enrollment suspended18-125 YearsNCI Tumor
000264-CA Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage ResponseParticipants currently recruited/enrolled18-120 YearsNCI Tumor
000254-CA Phase II Trial of the Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)Participants currently recruited/enrolled18-125 YearsNCI Tumor
000194-CA Phase I Trial of ProAgio, an anti- alpha-v-beta3 Integrin Cytotoxin, for Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor MalignanciesParticipants currently recruited/enrolled18-120 YearsNCI Tumor
000193-CPhase 1 Study of Copanlisib with Dose-adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and other High-Grade B-cell LymphomasCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
000176-CA Phase I/II Trial of Lurbinectedin with Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High Grade Neuroendocrine CancersParticipants currently recruited/enrolled18-125 YearsNCI Tumor
000144-CA Phase I/II Study of Sacituzumab Govitecan plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP InhibitorsClinical hold/Recruitment or enrollment suspended18-125 YearsNCI Tumor
000115-CA Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants with Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants with Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Booster DCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
000114-CA Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination with the Immunocytokine M9241 in Localized High and Intermediate Risk Prostate Cancer Treated with Androgen Deprivation TherapyParticipants currently recruited/enrolled18-125 YearsNCI Tumor
000096-CA Phase II study of Immunotherapy Combination: Irradiated PD-L1 CAR-NK cells plus Pembrolizumab plus N-803 for Subjects with Recurrent/Metastatic Gastric or Head and Neck CancerParticipants currently recruited/enrolled18-120 YearsNCI Tumor
000092-CPhase 1/2 study of Vincristine and Temozolomide in Combination with PEN-866 for Adolescents and Young Adults with Relapsed or Refractory Solid TumorsRecruitment has not started12-39 YearsNCI Tumor
000085-CAssessing Sleep and Circadian Rhythms in Primary Brain Tumors Patients: An Observational StudyEnrolling by Invitation18-99 YearsNCI Tumor
000081-CA Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell SarcomaCompleted Study; data analyses ongoing2-125 YearsNCI Tumor
000080-C18F-DCFPyL PET/CT in Hepatocellular CarcinomaParticipants currently recruited/enrolled18-125 YearsNCI Tumor
000079-DKThe Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid CancerParticipants currently recruited/enrolled18-98 YearsNIDDKTumor
000067-CUnderstanding the Patient Experience: Symptom Burden in Pediatric Patients Receiving Chimeric Antigen Receptor (CAR) T-cell TherapyCompleted Study; data analyses ongoing2-125 YearsNCI Tumor
000059-CPhase I Study of Intratumor Injection of anti-Mesothelin Immunotoxin LMB-100 with Ipilimumab in Malignant MesotheliomaCompleted Study; data analyses ongoing18-120 YearsNCI Tumor
000048-CA Multi-Center Natural History Study of Precision-Based Genomics in Prostate CancerParticipants currently recruited/enrolled18-125 YearsNCI Tumor
000045-CA Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and other KK-LC-1 Positive Epithelial CancersParticipants currently recruited/enrolled18-120 YearsNCI Tumor
000030-CPhase 2 Study of Bintrafusp alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).No longer recruiting/follow-up only18-125 YearsNCI Tumor
22-C-0005Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Recurrent Small Cell Lung CancerParticipants currently recruited/enrolled18-125 YearsNCI Tumor
22-C-0004A Phase II Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell CancerParticipants currently recruited/enrolled12-120 YearsNCI Tumor
22-C-0003Feasibility of Evaluating Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral MicrodialysisParticipants currently recruited/enrolled18-39 YearsNCI Tumor
21-I-0029Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)Participants currently recruited/enrolled3-125 YearsNIAIDTumor
21-C-0032GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Osteosarcoma or Neuroblastoma to Increase Systemic Tumor ExposureParticipants currently recruited/enrolled0-40 YearsNCI Tumor
21-C-0030Phase I Study of GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)Participants currently recruited/enrolled18-125 YearsNCI Tumor
21-C-0026A Phase I/II Study of Abemaciclib in Patients with HIV-associated and HIV-negative Kaposi SarcomaParticipants currently recruited/enrolled18-125 YearsNCI Tumor
21-C-0024A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple MyelomaNo longer recruiting/follow-up only18-125 YearsNCI Tumor
21-C-0023A Phase I Study of Pomalidomide and Nivolumab in Patients with Virus-Associated Malignancies with or without HIVParticipants currently recruited/enrolled18-125 YearsNCI Tumor
21-C-0022A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR(TM) T Cells in Subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell LiposarcomaParticipants currently recruited/enrolled10-75 YearsNCI Tumor
21-C-0021SARC037: A Phase I Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour Infusion in Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3'Deoxy-3'-18F Fluorothymidine (18F-FLT) ImagingNo longer recruiting/follow-up only6-125 YearsNCI Tumor
21-C-0019Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients with Relapsed/Refractory Hairy Cell Leukemia and VariantParticipants currently recruited/enrolled18-125 YearsNCI Tumor
21-C-0015Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment with Immune Checkpoint Inhibition (ICI) in Patients with Newly Diagnosed Glioblastoma or GliosarcomaParticipants currently recruited/enrolled18-125 YearsNCI Tumor
21-C-0012Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis from Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma HistologiesParticipants currently recruited/enrolled18-125 YearsNCI Tumor
21-C-0011A Phase 0/I/II Study of the Cyclin-Dependent Kinase(CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type 1 (NF1) Related Atypical NeurofibromasParticipants currently recruited/enrolled12-125 YearsNCI Tumor
21-C-0009A Natural History Study of Children and Adults with Olfactory NeuroblastomaParticipants currently recruited/enrolled3-120 YearsNCI Tumor
21-C-0007A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon CancersParticipants currently recruited/enrolled18-120 YearsNCI Tumor
21-C-0006Phase II Study Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract CancersParticipants currently recruited/enrolled18-125 YearsNCI Tumor
21-C-0001A Phase I/II Study of M9241 with Docetaxel and Abiraterone in Adults with Metastatic Castration Sensitive and M9241 with Docetaxel in Castration Resistant Prostate CancerParticipants currently recruited/enrolled18-125 YearsNCI Tumor
20-N-0048Corticotrophin-Releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in Cushing's DiseaseRecruitment has not started8-125 YearsNINDSTumor
20-N-0019The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's DiseaseParticipants currently recruited/enrolled18-125 YearsNINDSTumor
20-CH-0165Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals with Androgen InsensitivityParticipants currently recruited/enrolled1-99 YearsNICHDTumor
20-CH-0126Data Collection Study of Pediatric and Adolescent Gynecology ConditionsParticipants currently recruited/enrolled0-100 YearsNICHDTumor
20-C-0162A Phase 1 Study of Venetoclax with Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell MalignanciesNo longer recruiting/follow-up only18-125 YearsNCI Tumor
20-C-0161Prospective Study of Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic AnalysisParticipants currently recruited/enrolled6-125 YearsNCI Tumor
20-C-0155Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination with BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) with CV301 TRICOM in Advanced Solid Tumors (STAT)Completed Study; data analyses ongoing18-120 YearsNCI Tumor
20-C-0154Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-expressing Advanced Solid TumorsParticipants currently recruited/enrolled18-120 YearsNCI Tumor
20-C-0149Phase II Trial of Olaparib (LYNPARZA) plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas that Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine TumorsParticipants currently recruited/enrolled18-125 YearsNCI Tumor
20-C-0142A Phase II Study of Bintrafusp alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects with Urothelial CarcinomaCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
20-C-0138Phase II Trial of Combination Immunotherapy in Subjects with Advanced Small Bowel and Colorectal CancersNo longer recruiting/follow-up only18-120 YearsNCI Tumor
20-C-0130A Feasibility Study Investigating the Use of Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor PainCompleted Study; data analyses ongoing12-120 YearsNCI Tumor
20-C-0127A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), dexamethasone, and lenalidomide (RAdR) for relapsed/refractory T-cell malignanciesNo longer recruiting/follow-up only18-125 YearsNCI Tumor
20-C-0121Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and PaclitaxelParticipants currently recruited/enrolled18-120 YearsNCI Tumor
20-C-0106Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients with BAP1 Tumor Predisposition SyndromeParticipants currently recruited/enrolled30-125 YearsNCI Tumor
20-C-0104Phase I/II Trial of HPV Vaccine PRGN-2009 Alone or in Combination with Anti-PD-L1/TGF-Beta Trap (M7824) in Subjects with HPV Positive CancersNo longer recruiting/follow-up only18-120 YearsNCI Tumor
20-C-0097A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects with Thymoma and Thymic CarcinomaParticipants currently recruited/enrolled18-125 YearsNCI Tumor
20-C-0069A First-In-Human Phase I Single-Agent Dose-Escalation and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System NeoplasmsParticipants currently recruited/enrolled18-125 YearsNCI Tumor
20-C-0065A Phase II Feasibility Trial Using Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) PatientsParticipants currently recruited/enrolled18-125 YearsNCI Tumor
20-C-0062A phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)Participants currently recruited/enrolled18-125 YearsNCI Tumor
20-C-0061Phase I/II study of NHS-IL12 Monotherapy and in Combination with M7824 in Advanced Kaposi SarcomaParticipants currently recruited/enrolled18-125 YearsNCI Tumor
20-C-0045Phase I/II Trial of Combination Immunotherapy in Subjects with Advanced HPV Associated MalignanciesNo longer recruiting/follow-up only18-125 YearsNCI Tumor
20-C-0024A Sequential Window of Opportunity Trial of Anti-PD-L1/TGF-beta trap (M7824 ) Alone and in Combination with TriAd Vaccine, and N-803 for Resectable Head and Neck Squamous Cell Carcinoma not Associated with Human Papillomavirus Infection.Completed Study; data analyses ongoing18-120 YearsNCI Tumor
20-C-0023First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects with Metastatic Solid TumorsParticipants currently recruited/enrolled12-120 YearsNCI Tumor
20-C-0022Phase II trial of VB-111 in Combination with Nivolumab in Patients with Metastatic Colorectal Cancer (mCRC)Completed Study; data analyses ongoing18-125 YearsNCI Tumor
20-C-0020Ex-Vivo Trial of En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope DeviceParticipants currently recruited/enrolled18-125 YearsNCI Tumor
20-C-0013Phase I/II Trial of PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell CancersNo longer recruiting/follow-up only18-125 YearsNCI Tumor
20-C-0012A Phase I Study of Bintrafusp alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination with Stereotactic Body Radiation Therapy (SBRT) in Adults with Metastatic Non-Prostate Genitourinary MalignanciesParticipants currently recruited/enrolled18-125 YearsNCI Tumor
20-C-0011Phase 1 Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for Patients with Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary SyndromeCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
20-C-0009Randomized Phase II Trial of Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in Patients with Relapsed Small-Cell Lung CancerNo longer recruiting/follow-up only18-125 YearsNCI Tumor
19-I-0084Skin Immunity Sample Collection Involving Blisters and BiopsiesEnrolling by Invitation7-65 YearsNIAIDTumor
19-H-0111Early Clonal Dynamics During Venetoclax Treatment for Chronic Lymphocytic Leukemia (CLL)Participants currently recruited/enrolled18-125 YearsNHLBITumor
19-DK-0050The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid CancerParticipants currently recruited/enrolled18-90 YearsNIDDKTumor
19-CH-0051Long-Term Follow-UP of Survivors of Pediatric Cushing DiseaseParticipants currently recruited/enrolled2-90 YearsNICHDTumor
19-C-0137A Phase II Study of Ipilimumab, Cabozantinib, and NIvolumab in Rare Genitourinary Cancers (ICONIC)Participants currently recruited/enrolled18-125 YearsNCI Tumor
19-C-0135Evaluation of the Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine TumorsParticipants currently recruited/enrolled12-125 YearsNCI Tumor
19-C-0128A Phase I Study of Mesothelin-Targeted Immunotoxin LMB-100 in Combination with Tofacitinib in Persons with Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and other Mesothelin Expressing Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
19-C-0123DURVA PLUS: Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination with Chemotherapy in Patients with Advanced Solid TumorsParticipants currently recruited/enrolled18-125 YearsNCI Tumor
19-C-0117A Phase 1 / 2 Single Arm Open-label Clinical Trial of Gavocabtagene Autoleucel (gavo-cel) in Patients with Advanced Mesothelin Expressing CancerNo longer recruiting/follow-up only18-120 YearsNCI Tumor
19-C-0116A Phase 2 Study of Acalabrutinib with DA-EPOCH-R or R-CHOP for Patients with Untreated Diffuse Large B-cell LymphomaParticipants currently recruited/enrolled18-125 YearsNCI Tumor
19-C-0103A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas with Secondary Involvement of the Central Nervous System (CNS)No longer recruiting/follow-up only18-125 YearsNCI Tumor
19-C-0102A Phase I Clinical Trial of T-cells Expressing an anti-SLAMF7 CAR for Treating Multiple MyelomaCompleted Study; data analyses ongoing18-73 YearsNCI Tumor
19-C-0096Studying the Biology of IDH-mutant Gliomas via Longitudinal Observation of 2-Hydroxyglutarate (2-HG) Using MR SpectroscopyParticipants currently recruited/enrolled18-125 YearsNCI Tumor
19-C-0094A Phase II Study of Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinoma (BTC)Participants currently recruited/enrolled18-125 YearsNCI Tumor
19-C-0085Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Peripheral T cell LymphomaParticipants currently recruited/enrolled12-120 YearsNCI Tumor
19-C-0082Natural History Study of Children and Adults with ChordomaParticipants currently recruited/enrolled2-125 YearsNCI Tumor
19-C-0061A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath TumorsCompleted Study; data analyses ongoing12-125 YearsNCI Tumor
19-C-0049Long Term Follow-up of Mesothelioma Patients and Their Family Members with Germline Mutations in BAP1 and Other GenesParticipants currently recruited/enrolled2-125 YearsNCI Tumor
19-C-0046Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.No longer recruiting/follow-up only18-125 YearsNCI Tumor
19-C-0041Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)Completed Study; data analyses ongoing18-125 YearsNCI Tumor
19-C-0039Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal CancersCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
19-C-0033Phase II Study of Nivolumab (anti-PD1), Tadalafil and Oral Vancomycin in Patients with Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer from Colorectal or Pancreatic CancersCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
19-C-0030A Phase 2 Study of Response-Adapted Therapy with Copanlisib and Rituximab in Untreated Follicular LymphomaNo longer recruiting/follow-up only18-125 YearsNCI Tumor
19-C-0025Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic MalignanciesEnrolling by Invitation18-125 YearsNCI Tumor
19-C-0023A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and other genitourinary tumors with DNA-Repair DefectsParticipants currently recruited/enrolled18-125 YearsNCI Tumor
19-C-0017A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 PatientsParticipants currently recruited/enrolled18-72 YearsNCI Tumor
19-C-0010A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
19-C-0006Phase II Trial Evaluating Nivolumab In Patients With IDH-Mutant Gliomas With And Without Hypermutator PhenotypeParticipants currently recruited/enrolled18-125 YearsNCI Tumor
18-N-0133Feasibility of Endosphenoidal Coil Placement for Imaging of the Sella During Transsphenoidal SurgeryParticipants currently recruited/enrolled18-85 YearsNINDSTumor
18-N-0077Cytokine Microdialysis For Real Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint BlockadeCompleted Study; data analyses ongoing18-125 YearsNINDSTumor
18-H-0012A Phase I Study of HERV-E TCR Transduced Autologous T Cells in Patients with Metastatic Clear Cell Renal Cell CarcinomaNo longer recruiting/follow-up only18-75 YearsNHLBITumor
18-D-0114An Open Label Pilot Study of Denosumab Treatment for Fibrous DysplasiaCompleted Study; data analyses ongoing18-125 YearsNIDCRTumor
18-CH-0031Clinical and Molecular Characteristics of Primary Aldosteronism in BlacksClinical hold/Recruitment or enrollment suspended7-70 YearsNIDDKTumor
18-C-0147Phase 1 with Expansion Cohorts in a Study of NEO-201 In Adults with Chemo-Resistant Solid TumorsParticipants currently recruited/enrolled18-125 YearsNCI Tumor
18-C-0143A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior ChemotherapyCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
18-C-0138An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma.No longer recruiting/follow-up only18-125 YearsNCI Tumor
18-C-0125A Phase I Clinical Trial of T cells Expressing a Novel Fully-human Anti-BCMA CAR for Treating Multiple MyelomaNo longer recruiting/follow-up only18-73 YearsNCI Tumor
18-C-0122Phase 1B Study of Copanlisib in Combination with Nivolumab or with Nivolumab and IpilimumabCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
18-C-0110Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell CancersParticipants currently recruited/enrolled18-99 YearsNCI Tumor
18-C-0102Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults with Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (cNF)Completed Study; data analyses ongoing18-125 YearsNCI Tumor
18-C-0093Pilot Study of Medication Adherence in Children, Adolescents, and Adults with Neurofibromatosis Type 1 (NF1) on Clinical Treatment TrialsCompleted Study; data analyses ongoing3-59 YearsNCI Tumor
18-C-0078A Phase I/II Study of Immunotherapy Combination BN-Brachyury vaccine, M7824, N-803 and Epacadostat (QuEST1)No longer recruiting/follow-up only18-120 YearsNCI Tumor
18-C-0062Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare TumorsCompleted Study; data analyses ongoing2-30 YearsNCI Tumor
18-C-0059Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell MalignanciesParticipants currently recruited/enrolled3-39 YearsNCI Tumor
18-C-0058A Pilot Study to Evaluate the Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration in Men with Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy FemalesCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
18-C-0056Phase II Trial of M7824 in Subjects with HPV Associated MalignanciesCompleted Study; data analyses ongoing18-120 YearsNCI Tumor
18-C-0049A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients with Metastatic CancerParticipants currently recruited/enrolled18-72 YearsNCI Tumor
18-C-0033Phase I Study of Recombinant Interleukin 15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in Subjects with Refractory CancersParticipants currently recruited/enrolled18-125 YearsNCI Tumor
18-C-0028A Phase I Trial of Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy RadiotherapyNo longer recruiting/follow-up only18-125 YearsNCI Tumor
18-C-0024A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy with Floxuridine and Dexamethasone in Combination with Systemic Chemotherapy for Patients with Colorectal Cancer Metastatic to the LiverParticipants currently recruited/enrolled18-125 YearsNCI Tumor
18-C-0014Phase I Trial of 5-aza-4'-thio-2'-Deoxycytidine (Aza-TdC) in Patients with Advanced Solid TumorsParticipants currently recruited/enrolled18-120 YearsNCI Tumor
18-C-0008Phase III Randomized Adjuvant study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) versus ObservationNo longer recruiting/follow-up only18-125 YearsNCI Tumor
17-H-0118A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)No longer recruiting/follow-up only18-100 YearsNHLBITumor
17-C-0174Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman DiseaseParticipants currently recruited/enrolled18-125 YearsNCI Tumor
17-C-0158A Feasibility Study of Mobile Sensor Technologies to Assess General Symptomology of Cancer PatientsEnrolling by Invitation18-120 YearsNCI Tumor
17-C-0157A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (oportuzumab monatox, VB4-845) in Subjects with High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated with Bacillus Calmette-Gu(SqrRoot)(Copyright)rin (BCG)Completed Study; data analyses ongoing18-125 YearsNCI Tumor
17-C-0153Phase I Trial of Image Guided Focally Dose Escalated Prostate SBRT for Locally Recurrent Prostate Cancer after Prior RadiotherapyNo longer recruiting/follow-up only18-125 YearsNCI Tumor
17-C-0140Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, Esophageal Carcinomas, or Pleural MesotheliomasCompleted Study; data analyses ongoing18-99 YearsNCI Tumor
17-C-0127Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaParticipants currently recruited/enrolled18-125 YearsNCI Tumor
17-C-0125Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin LymphomasParticipants currently recruited/enrolled12-125 YearsNCI Tumor
17-C-0115Phase I/II Study of T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic RadiosurgeryCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
17-C-0113A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 PatientsParticipants currently recruited/enrolled18-72 YearsNCI Tumor
17-C-0102Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS CancersParticipants currently recruited/enrolled18-99 YearsNCI Tumor
17-C-0100Collection of Malignant Ascites, Pleural Fluid and Blood from Patients with Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
17-C-0092A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal CancerCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
17-C-0089Evaluation of 18F-DCFPyL PSMA- versus 18F-NaF-PET imaging for Detection of Metastatic Prostate CancerEnrolling by Invitation18-125 YearsNCI Tumor
17-C-0087Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ ParagangliomaParticipants currently recruited/enrolled18-125 YearsNCI Tumor
17-C-0086An Open-label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell CarcinomaNo longer recruiting/follow-up only18-125 YearsNCI Tumor
17-C-0074A Phase 2 Study of Anti-PD-L1 Antibody Atezolizumab in Alveolar Soft Part SarcomaNo longer recruiting/follow-up only2-125 YearsNCI Tumor
17-C-0070Phase II Trial of Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer with Positive Peritoneal CytologyNo longer recruiting/follow-up only18-125 YearsNCI Tumor
17-C-0066A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma after Progression on Platinum-Based ChemotherapyParticipants currently recruited/enrolled18-125 YearsNCI Tumor
17-C-0061Phase II Trial of Pembrolizumab in Recurrent or Metastatic Medullary Thyroid CancerCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
17-C-0048Anti-CD30 CAR T Cells with Fully-human Binding Domains for Treating CD30-expressing Lymphomas Including Anaplastic Large Cell LymphomasCompleted Study; data analyses ongoing18-73 YearsNCI Tumor
17-C-0045A Phase I Study of Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and LymphomasCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
17-C-0044Prospective Evaluation and Molecular Profiling in Patients with Gastric TumorsParticipants currently recruited/enrolled2-125 YearsNCI Tumor
17-C-0037Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent GlioblastomaCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
17-C-0034A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab with and without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)Completed Study; data analyses ongoing18-125 YearsNCI Tumor
17-C-0011Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes with Sylatron(R) (Peginterferon alfa-2b) and Actimmune(R) (Interferon gamma-1b) in Women with Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal CancerCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
17-C-0009Phase I Trial of Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide (tmz) Followed by Randomized Phase II Trial of Zotiraciclib (TG02) plus Temozolomide versus Temozolomide alone in Adults with Recurrent Anaplastic Astrocytoma and GlioblastomCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
17-C-0007Phase I/II Study of PROSTVAC in Combination with Nivolumab in Men with Prostate CancerCompleted Study; data analyses ongoing18-120 YearsNCI Tumor
16-N-0041Tumor Related EpilepsyParticipants currently recruited/enrolled8-99 YearsNINDSTumor
16-CC-0098Pilot Study of Ultrasound Guided Focal Thermal Ablation of Prostate CancerClinical hold/Recruitment or enrollment suspended18-100 YearsCC Tumor
16-CC-0049A Phase II Study Using LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors During Treatment with Transarterial Embolization (TAE) Alone or Combined with Thermal AblationCompleted Study; data analyses ongoing18-100 YearsCC Tumor
16-C-0151Evaluation of the Natural History of and Specimen Banking for Patients with Tumors of the Central Nervous SystemNo longer recruiting/follow-up only18-125 YearsNCI Tumor
16-C-0138Collection of Peripheral Blood Mononuclear Cells (PBMCs) from Healthy Subjects for the Expansion of T Cells for Adoptive Cell TherapyParticipants currently recruited/enrolled18-120 YearsNCI Tumor
16-C-0135A Pilot Study of Combined Immune Checkpoint Inhibition in combination with Ablative Therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)Completed Study; data analyses ongoing18-125 YearsNCI Tumor
16-C-0131A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a CD70-Binding Chimeric Antigen Receptor to Patients with CD70-Expressing CancersParticipants currently recruited/enrolled18-72 YearsNCI Tumor
16-C-0128A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
16-C-0121A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial CarcinomaCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
16-C-0107A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin with Olaparib in Patients with Relapsed/Refractory Small Cell Lung, Bladder and Prostate CancersParticipants currently recruited/enrolled18-125 YearsNCI Tumor
16-C-0097Phase 1 Trial of Panobinostat in Children with Diffuse Intrinsic Pontine GliomaCompleted Study; data analyses ongoing2-21 YearsNCI Tumor
16-C-0092A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment with Osimertinib (AZD9291, Tagrisso)Completed Study; data analyses ongoing18-125 YearsNCI Tumor
16-C-0088A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary PeritoneaCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
16-C-0087Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor in Combination with Cisplatin in Patients with Refractory Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
16-C-0081A Phase I Dose Escalation Trial of Re-Irradiation in Good Prognosis Recurrent GlioblastomaCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
16-C-0073A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian CancerCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
16-C-0061Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy ProtocolsParticipants currently recruited/enrolled18-120 YearsNCI Tumor
16-C-0048Docetaxel and Prostvac for Metastatic Castration Sensitive Prostate CancerCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
16-C-0043Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform NeurofibromasNo longer recruiting/follow-up only18-125 YearsNCI Tumor
16-C-0035Prostvac in Patients with Biochemically Recurrent Prostate CancerCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
16-C-0034A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior BevacizumabCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
16-C-0027A Prospective Randomized and Phase II Trial for Metastatic Melanoma Using Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of PembrolizumabClinical hold/Recruitment or enrollment suspended18-70 YearsNCI Tumor
16-C-0011A Phase I-II Trial of Everolimus and Sorafenib in Patients with Recurrent High-Grade GliomasCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
16-C-0010Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer TissueParticipants currently recruited/enrolled18-125 YearsNCI Tumor
16-C-0009Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center TrialCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
15-H-0172A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)No longer recruiting/follow-up only18-125 YearsNHLBITumor
15-H-0016A Phase II Study Using ACP-196 in Patients with Relapsed/Refractory and Treatment Naive Deletion 17p CLL/SLL: Pharmacodynamic Assessment of BTK Inhibition and Anti-Tumor Response.No longer recruiting/follow-up only18-125 YearsNHLBITumor
15-D-0129Open-Label, Dose-Escalation Study Evaluating the Safety of a Single Administration of an Adeno-Associated Virus Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in Individuals with Irradiation-Induced Parotid Salivary Hypofunction.No longer recruiting/follow-up only18-100 YearsNIDCRTumor
15-C-0200Molecular Analysis for Therapy Choice (MATCH) (EAY131)Completed Study; data analyses ongoing18-125 YearsNCI Tumor
15-C-0160A Phase I Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary TumorsNo longer recruiting/follow-up only18-125 YearsNCI Tumor
15-C-0157Phase I/II Trial of Vandetanib in Combination with Metformin in Subjects with HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell CarcinomaCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
15-C-0150A Phase I/II Trial of Topotecan with VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell CancersNo longer recruiting/follow-up only18-125 YearsNCI Tumor
15-C-0145Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination with Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal CancersParticipants currently recruited/enrolled18-125 YearsNCI Tumor
15-C-0142Acceptance and Commitment Training for Adolescents and Adults with Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain: A Phase III Clinical TrialCompleted Study; data analyses ongoing16-59 YearsNCI Tumor
15-C-0116Phase I Trial of 4'-thio-2'-deoxycytidine (TdCyd) in Patients With Advanced Solid TumorsClinical hold/Recruitment or enrollment suspended18-120 YearsNCI Tumor
15-C-0093Phase I Trial of TURALIO (pexidartinib, PLX3397) in Children and Young Adults with Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCTParticipants currently recruited/enrolled3-35 YearsNCI Tumor
15-C-0087Care of the Urothelial Cancer Patient and Prospective Collection of Biospecimens from Healthy Volunteers and Urothelial Cancer PatientsParticipants currently recruited/enrolled18-125 YearsNCI Tumor
15-C-0086Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults and Pediatric Patients with Refractory Solid TumorsParticipants currently recruited/enrolled12-120 YearsNCI Tumor
15-C-0076A Pilot Study of Long Term TARP Vaccination Using A Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139Completed Study; data analyses ongoing18-125 YearsNCI Tumor
15-C-0075A Randomized, Placebo-Controlled Phase II Study of Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men with Stage D0 Prostate CancerCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
15-C-0029Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-expressing B Cell MalignanciesNo longer recruiting/follow-up only3-39 YearsNCI Tumor
15-C-0028Follow-Up Evaluation for Gene-Therapy Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical TrialsEnrolling by Invitation1-99 YearsNCI Tumor
15-C-0019The Impact of Ras/MAPK Signaling Pathway-Targeted Therapies on Neurocognitive Functioning in Individuals with NF1Completed Study; data analyses ongoing4-99 YearsNCI Tumor
14-CH-0028Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing SyndromeParticipants currently recruited/enrolled18-80 YearsNIDDKTumor
14-C-0163Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Clinical, Histopathologic, and Genomic AnalysisCompleted Study; data analyses ongoing10-125 YearsNCI Tumor
14-C-0161Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults with Refractory Solid Tumors, Lymphomas, or Myelodysplastic SyndromesParticipants currently recruited/enrolled18-120 YearsNCI Tumor
14-C-0156A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian CancerCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
14-C-0128Collection of Pharmacokinetic and Probe Substrate Samples from Participants with Unanticipated Response, Significant Toxicity or Concern of Future ToxicityEnrolling by Invitation2-125 YearsNCI Tumor
14-C-0116A Randomized Controlled Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated with Cranial Radiation for Brain TumorsParticipants currently recruited/enrolled8-125 YearsNCI Tumor
14-C-0105Tissue Procurement and Natural History Study of Patients with Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial TumorsParticipants currently recruited/enrolled18-125 YearsNCI Tumor
14-C-0104A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes Derived from Patients with Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative RegimenParticipants currently recruited/enrolled18-72 YearsNCI Tumor
14-C-0037A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell CancerCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
14-C-0036A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination with PANVAC[TM] Versus BCG Given Alone in Adults with High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 ICompleted Study; data analyses ongoing18-125 YearsNCI Tumor
14-C-0001Phase II Study of Axitinib (AG-013736) with Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/ParagangliomaCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
13-C-0202Tissue Procurement and Natural History Study of Patients with Malignant Mesothelioma and Other Mesothelin Expressing CancersParticipants currently recruited/enrolled2-125 YearsNCI Tumor
13-C-0176Tumor, Normal Tissue and Specimens from Patients Undergoing Evaluation or Surgical Resection of Solid TumorsClinical hold/Recruitment or enrollment suspended2-125 YearsNCI Tumor
13-C-0152A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults with Refractory Solid TumorsCompleted Study; data analyses ongoing2-29 YearsNCI Tumor
13-C-0131Inpatient Hospice with Procurement of Tissue on Expiration in Thoracic Malignancies, Bladder Cancer, Ovarian Cancer, Epithelial Cancer and Patients Treated with an Adoptive Cellular TherapyParticipants currently recruited/enrolled18-120 YearsNCI Tumor
13-C-0119Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided BiopsiesParticipants currently recruited/enrolled18-125 YearsNCI Tumor
13-C-0118A Phase I/II Trial of TRC102 (methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and LymphomasCompleted Study; data analyses ongoing18-120 YearsNCI Tumor
13-C-0105Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid TumorsCompleted Study; data analyses ongoing18-120 YearsNCI Tumor
13-C-0095A Phase 2 Study of GI-6207 in Patients with Recurrent Medullary Thyroid CancerCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
13-AR-0056Stopping Tumor Necrosis Factor-Alpha Inhibitors in Rheumatoid ArthritisCompleted Study; data analyses ongoing18-125 YearsNIAMSTumor
12-C-0205A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial CarcinomaCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
12-C-0193Lymphoid Malignancies and Precursors: Tissue Acquisition ProtocolParticipants currently recruited/enrolled18-125 YearsNCI Tumor
12-C-0178Longitudinal Assessment and Natural History Study of Children and Adults with MEN2A or MEN2B with or without Medullary Thyroid CarcinomaParticipants currently recruited/enrolled0-125 YearsNCI Tumor
12-C-0118A Phase II Study of Sunitinib in Patients with Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma with at Least One Prior Line of Platinum-Based Systemic ChemotherapyNo longer recruiting/follow-up only18-100 YearsNCI Tumor
12-C-0081Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast CancerNo longer recruiting/follow-up only18-125 YearsNCI Tumor
12-C-0079A Phase II Multicenter Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate CancerCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
12-C-0066Phase I Trial of Oral 5-Fluoro-2'-Deoxycytidine with Oral Tetrahydrouridine in Patients with Advanced Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
11-N-0051Surgery as a Treatment for Medically Intractable EpilepsyParticipants currently recruited/enrolled8-99 YearsNINDSTumor
11-C-0247A Randomized Phase II Study of Tecemotide in Combination with Standard Androgen Deprivation Therapy and Radiation Therapy for untreated, intermediate and High Risk Prostate Cancer PatientsCompleted Study; data analyses ongoing18-100 YearsNCI Tumor
11-C-0242Collection of Blood from Patients with Cancer, Other Tumors, or Tumor Predisposition Syndromes for Analysis of Genetic Differences in Drug DispositionParticipants currently recruited/enrolled3-125 YearsNCI Tumor
11-C-0220Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)Participants currently recruited/enrolled18-125 YearsNCI Tumor
11-C-0200A Phase II Trial In Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, with Cross-Over at Disease ProgressionNo longer recruiting/follow-up only16-120 YearsNCI Tumor
11-C-0190Collection of Tissue Blocks or Slides from Patients with CancerParticipants currently recruited/enrolled18-125 YearsNCI Tumor
11-C-0161A Phase I/II Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; Hydrogen Sulfate in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)No longer recruiting/follow-up only2-18 YearsNCI Tumor
11-C-0140A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients with Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
11-C-0123A Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor-Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction withNo longer recruiting/follow-up only18-66 YearsNCI Tumor
11-C-0112Acquisition of Blood and Tumor Tissue Samples from Patients with Gastrointestinal CancerParticipants currently recruited/enrolled18-125 YearsNCI Tumor
11-C-0096Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic MalignanciesNo longer recruiting/follow-up only18-125 YearsNCI Tumor
11-C-0061Phase I Trial of Z-Endoxifen in Adults with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or other Hormone Receptor-Positive Solid TumorsNo longer recruiting/follow-up only18-120 YearsNCI Tumor
11-C-0034DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History StudyParticipants currently recruited/enrolled0-125 YearsNCI Tumor
10-E-0134Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA DamageCompleted Study; data analyses ongoing18-100 YearsNIEHSTumor
10-DK-0102Clinical and Genetic Studies in Familial Non-Medullary Thyroid CancerParticipants currently recruited/enrolled7-90 YearsNIDDKTumor
10-C-0166A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of PembrolizumabParticipants currently recruited/enrolled18-72 YearsNCI Tumor
10-C-0114A Phase II Study of Bevacizumab and Erlotinib in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell CancerCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
10-C-0086Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological StudiesParticipants currently recruited/enrolled0-125 YearsNCI Tumor
10-C-0066A Study of Hairy Cell and other Leukemias with a Focus on Recombinant Immunotoxins for Cancer TreatmentParticipants currently recruited/enrolled18-125 YearsNCI Tumor
10-C-0056A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and LymphomasCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
10-C-0054Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells from the Original Transplant Donor to Patients with Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell TransplantationCompleted Study; data analyses ongoing18-75 YearsNCI Tumor
10-C-0025Randomized Phase II Trial of Rituximab with Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell LeukemiaNo longer recruiting/follow-up only18-125 YearsNCI Tumor
10-C-0011Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin LymphomasCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
09-I-0086Screening Protocol for Genetic Diseases of Allergic InflammationCompleted Study; data analyses ongoing0-99 YearsNIAIDTumor
09-C-0242Prospective Comprehensive Molecular Analysis of Endocrine NeoplasmsParticipants currently recruited/enrolled4-125 YearsNCI Tumor
09-C-0192Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part SarcomaNo longer recruiting/follow-up only0-125 YearsNCI Tumor
09-C-0161Follow-Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch StudiesEnrolling by Invitation18-125 YearsNCI Tumor
09-C-0100A Pilot Study of High Dose Rate Brachytherapy in The Radiation Oncology BranchNo longer recruiting/follow-up only18-125 YearsNCI Tumor
09-C-0019A Phase I Study of Dasatinib in Combination with Bevacizumab in Advanced Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
09-C-0005Randomized Trial of Cladribine (CdA) with Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual DiseaseNo longer recruiting/follow-up only18-125 YearsNCI Tumor
08-N-0044A Prospective Natural History Study of Patients with Neurofibromatosis Type 2 (NF2).Participants currently recruited/enrolled8-75 YearsNINDSTumor
08-H-0186Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity with BortezomibCompleted Study; data analyses ongoing18-70 YearsNHLBITumor
08-C-0130A Phase II Trial of Peginterferon alfa-2b (PEG-Intron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform NeurofibromasCompleted Study; data analyses ongoing0-21 YearsNCI Tumor
08-C-0079Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type 1No longer recruiting/follow-up only0-125 YearsNCI Tumor
08-C-0020A Phase II Study of ZD6474 (Vandetanib) in Patients with Von Hippel Lindau Disease and Renal TumorsCompleted Study; data analyses ongoing18-120 YearsNCI Tumor
07-CH-0008Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) SecretionCompleted Study; data analyses ongoing18-85 YearsNIDDKTumor
07-C-0121Phase 2 Study of the C-Met RTK Inhibitor Foretinib (Formerly GSK 1363089) in Subjects with Papillary Renal Cell Carcinoma (PRC)Completed Study; data analyses ongoing18-125 YearsNCI Tumor
07-C-0110Analysis of Stored Data Collected from Individuals Administered Neurobehavioral Assessments on IRB-Approved ProtocolsEnrolling by Invitation0-125 YearsNCI Tumor
06-C-0219An Exploratory Study of Biologic and Pathophysiologic Effects of Radiation Therapy in Pediatric Patients with Central Nervous System TumorsCompleted Study; data analyses ongoing0-21 YearsNCI Tumor
06-C-0213Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)Participants currently recruited/enrolled0-125 YearsNCI Tumor
06-C-0134Natural History and Biology of Dermal Neurofibromas in Neurofibromatosis Type 1Completed Study; data analyses ongoing20-99 YearsNCI Tumor
06-C-0014Prospective Evaluation of Genetic and Epigenetic Alterations in Patients with Thoracic MalignanciesParticipants currently recruited/enrolled2-125 YearsNCI Tumor
05-H-0130Long-Term Evaluation and Follow Up Care of Patients Treated with Allogeneic Stem Cell TransplantsParticipants currently recruited/enrolled7-80 YearsNHLBITumor
05-CC-0091Electromagnetic Tracking of Devices During Interventional ProceduresEnrolling by Invitation18-120 YearsCC Tumor
05-C-0252Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated de Novo Diffuse Large B-Cell LymphomasCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
05-C-0152Variation in Gene Expression in Neurofibromatosis Type 1Completed Study; data analyses ongoing2-100 YearsNCI Tumor
04-H-0012Collection of Blood, Bone Marrow, Urine, and/or Tissue Samples from Patients with Solid Tumors, Hematological Malignancies or Non-Malignant Hematologic Disorders or HLA Compatible Family MembersParticipants currently recruited/enrolled2-100 YearsNHLBITumor
04-C-0275Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease with Laboratory and Clinical Correlates of Disease ActivityNo longer recruiting/follow-up only18-125 YearsNCI Tumor
04-C-0274Follow-Up Study of Subjects Previously Enrolled in Immunotherapy Studies Utilizing Gene Transfer or Other Immunotherapeutic AgentsParticipants currently recruited/enrolled18-125 YearsNCI Tumor
04-C-0238A Phase 2 Study of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Von Hippel Lindau Disease and Renal TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
04-C-0232A Multi-Institutional Study of Proteomic Evaluation of Epithelial Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile of RelapseCompleted Study; data analyses ongoing18-125 YearsNCI Tumor
04-C-0200Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for RecurrenceParticipants currently recruited/enrolled18-125 YearsNCI Tumor
04-C-0102Hematologic Malignancy Biology StudyEnrolling by Invitation1-75 YearsNCI Tumor
03-N-0164Evaluation and Treatment of Neurosurgical DisordersParticipants currently recruited/enrolled4-99 YearsNINDSTumor
03-C-0277Cell Harvest and Preparation for Surgery Branch Treatment ProtocolsEnrolling by Invitation18-125 YearsNCI Tumor
03-C-0066Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene, and Characterization of the Predisposition to Renal CancerParticipants currently recruited/enrolled2-125 YearsNCI Tumor
02-H-0250A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning with Campath-1HCompleted Study; data analyses ongoing18-100 YearsNHLBITumor
02-C-0212Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian CancerCompleted Study; data analyses ongoing18-100 YearsNCI Tumor
02-C-0211Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of MelanomaParticipants currently recruited/enrolled0-125 YearsNCI Tumor
02-C-0210Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Blood and Lymph Node MalignancyNo longer recruiting/follow-up only0-125 YearsNCI Tumor
02-C-0178Multidisciplinary Etiologic Study of Familial Testicular CancerNo longer recruiting/follow-up only12-125 YearsNCI Tumor
02-C-0159Birt-Hogg-Dub(SqrRoot)(Copyright) Syndrome: Characterization of the FLCN Disease Gene and Predisposition to Renal Cancer, Cutaneous Fibrofolliculoma and Pulmonary CystsParticipants currently recruited/enrolled2-125 YearsNCI Tumor
02-C-0064Collection of Peripheral Blood and/or Urine From Patients Undergoing Radiation TherapyEnrolling by Invitation18-125 YearsNCI Tumor
02-C-0052Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History StudyParticipants currently recruited/enrolled0-100 YearsNCI Tumor
01-D-0184A Natural History Study of Bone and Mineral DisordersParticipants currently recruited/enrolled0-125 YearsNIDCRTumor
01-C-0038Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with HIV Infection, KSHV Infection, Viral-Related Pre-Malignant Lesions, and/or CancerParticipants currently recruited/enrolled18-125 YearsNCI Tumor
00-N-0140A Prospective Natural History Study of VHL Patients with CNS HemangioblastomasNo longer recruiting/follow-up only8-75 YearsNINDSTumor
00-H-0051Cutaneous Tumorigenesis in Patients with Tuberous SclerosisParticipants currently recruited/enrolled18-90 YearsNHLBITumor
00-CH-0160Clinical and Molecular Analysis of ACTH-Independent Steroid Hormone Production in Adrenocortical TissueCompleted Study; data analyses ongoing3-70 YearsNICHDTumor
00-CH-0093Diagnosis, Pathophysiology, and Molecular Biology of Pheochromocytoma and ParagangliomaParticipants currently recruited/enrolled3-120 YearsNICHDTumor
99-C-0128Evaluation for NCI Surgery Branch Clinical Research ProtocolsParticipants currently recruited/enrolled18-125 YearsNCI Tumor
97-CH-0076A Clinical and Genetic Investigation of Pituitary and HYPOTHALAMIC Tumors and Related DisordersParticipants currently recruited/enrolled3-70 YearsNICHDTumor
95-CH-0059Definition of the Genotype and Clinical Phenotype of Primary Pigmented Nodular Adrenocortical Disease (PPNAD), Carney Complex, Peutz-Jeghers Syndrome and Related ConditionsCompleted Study; data analyses ongoing3-70 YearsNICHDTumor
94-I-0079Eosinophil Activation and Function in Parasitic Infections and Other Conditions with Increased Tissue or Peripheral Blood Eosinophilia in HumansParticipants currently recruited/enrolled1-100 YearsNIAIDTumor
94-HG-0132The Phenotype and Etiology of Proteus SyndromeParticipants currently recruited/enrolled0-99 YearsNHGRITumor
94-C-0074Treatment and Natural History Study of Lymphomatoid GranulomatosisNo longer recruiting/follow-up only12-125 YearsNCI Tumor
90-DK-0137Evaluation of the Gastrinoma in Patients with Zollinger-Ellison SyndromeCompleted Study; data analyses ongoing18-100 YearsNIDDKTumor
78-C-0039Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of CancerNo longer recruiting/follow-up only0-125 YearsNCI Tumor
77-DK-0002Natural History of Thyroid Function DisordersParticipants currently recruited/enrolled0-98 YearsNIDDKTumor
10 Center Drive,Bethesda, MD 20892 | Directions
Privacy Statement | Accessibility | Plain Language | FOIA | Disclaimer
Clinical Center | National Institutes of Health | HHS Vulnerability Disclosure | U.S. Department of Health and Human Services | USA.gov
NIH…Turning Discovery Into Health®